Cardiac disease in Ankylosing Spondylitis

Completed

• Conditions: Ankylosing Spondylitis; 10028593; 10003216

• Registration Number: NL-OMON41462
• Lead Sponsor: Jan van Breemen Instituut

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 400

Inclusion Criteria

Ankylosing Spondyilitis according to New York (1984) criteria
Written informed consent
Age 50-75 years

Exclusion Criteria

Malignant disease

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Diastolic dysfunction will be defined as follows: mild diastolic dysfunction<br /><br>(stage I*impaired relaxation). Characterized by an E/A ratio <1, Em/Am <1,<br /><br>prolonged DT (>240 ms), and IVRT (>110 ms). Em (<8 cm/s) is reduced. E/Em is<br /><br><10. Moderate diastolic dysfunction (stage II* pseudo normalization).<br /><br>Characterized by an E/A ratio >1, Em/Am <1. Em (<8 cm/s) is reduced and E/Em is<br /><br>>10. Severe diastolic dysfunction (stage III* restrictive filling). This stage<br /><br>is characterized by an overt increased E/A ratio (>2), shortened DT (<150 ms),<br /><br>and IVRT (<60 ms). Em (<8 cm/s) remains at the lowest level. E/Em is >10.<br /><br>(13,20)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Systolic dysfunction will be defined as an ejection fraction of <50%.</p><br>